Although targeted drugs have been developed, the response rate may reach 80% in melanoma but just 5% in CRC, eliciting the urgent need for mechanistic research on the poor prognosis of BRAF V600E CRC patients. This evidence concerns the gene BRAF and colorectal carcinoma.